AbCellera Biologics logo
AbCellera Biologics ABCL
$ 3.34 -1.47%

Annual report 2025
added 02-24-2026

report update icon

AbCellera Biologics Net Debt 2011-2026 | ABCL

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt AbCellera Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
14.7 M -91 M -80.9 M -329 M -461 M -592 M -3.72 M -7 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
14.7 M -592 M -194 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.38 -0.58 % $ 367 M britainBritain
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.72 3.24 % $ 8.95 B australiaAustralia
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.6 -2.29 % $ 16.3 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
17.7 M $ 6.31 -1.79 % $ 180 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
-191 M $ 7.79 -0.51 % $ 494 K usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
-25.6 M $ 2.22 -13.28 % $ 142 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Gilead Sciences Gilead Sciences
GILD
14.7 B $ 138.97 -0.83 % $ 173 B usaUSA
Genmab A/S Genmab A/S
GMAB
-6.94 B $ 27.51 -0.86 % $ 17.3 B danmarkDanmark
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Gossamer Bio Gossamer Bio
GOSS
-33.3 M $ 0.32 -6.5 % $ 73.1 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.03 -2.43 % $ 6.83 B spainSpain
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
GT Biopharma GT Biopharma
GTBP
-5.5 M $ 0.41 -6.9 % $ 2.26 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
1.27 B $ 63.53 0.71 % $ 7.61 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
BioNTech SE BioNTech SE
BNTX
-973 M $ 89.39 -2.07 % $ 27.2 B germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
-85.6 M $ 1.64 -2.1 % $ 192 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M $ 3.53 -0.28 % $ 238 B britainBritain
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
-608 M $ 27.66 -0.18 % $ 1.59 B usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 319.97 -3.14 % $ 41.9 B usaUSA
iBio iBio
IBIO
-5.89 M $ 2.11 3.69 % $ 22.2 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
3.77 M $ 6.6 -0.15 % $ 59.6 M usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
-84.9 M $ 30.88 -4.51 % $ 2.73 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-32.3 M $ 0.97 2.89 % $ 152 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Immutep Limited Immutep Limited
IMMP
-17.4 M $ 0.35 -3.08 % $ 1.08 B australiaAustralia
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Immuron Limited Immuron Limited
IMRN
-21.9 M $ 0.82 -0.12 % $ 6.29 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
-3.06 B $ 94.06 -0.84 % $ 18.4 B usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA